3 New Strong Buy Ratings from Top-Rated Analysts: 11/25/2025

Solid investing ideas, delivered. Here’s what’s trending on our Strong Buy Stocks from Top Wall Street Analysts screener:

• Tenet Healthcare (THC) is an A-rated stock in an A-rated industry
• Sandisk Corp (SNDK) is the #1-ranked stock in its industry 
• Jazz Pharmaceuticals (JAZZ) is gaining serious momentum

P.S. Get more alerts like this daily … Try WallStreetZen Premium.

A note from our sponsors...

1. Tenet Healthcare (NYSE: THC)

Tenet Healthcare Corporation is quickly emerging as one of the most resilient players in the medical care facilities sector. Its nationwide network of acute and critical care hospitals is performing at a high level, and its recent Q3 earnings beat highlights that strength in real time. Even amid policy uncertainty, Tenet continues to execute—making it a stock investors may want to watch closely as momentum builds.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $210.20 — get current quote

Max 1-year forecast: $260.00

Why we're watching:

• Analyst support: THC has strong coverage among the analysts we track, with 12 Strong Buy ratings, 3 Buy ratings, and only 1 Hold rating. See the ratings
• For example, UBS researcher A.J. Rice (a top 11% rated analyst) recently maintained his Strong Buy rating with a $260 price target (+35.44% upside), representing the highest forecast among analysts following the company. 
• Industry ranking context: THC is currently the 7th highest-rated stock in the Medical Care Facility industry, which has an Industry Rating of A. (See all the stocks in the industry here.)
• Zen Rating highlights: With its A (Strong Buy) Zen Rating, THC is in a class of stocks averaging +32.52%/yr, significantly higher than the broader market.
• Component Grades: Looking at the individual scores that make up the overall grade, the company earns B grades in Value, Sentiment, and Financials, with particularly strong return on equity of 44.92% and expected EPS growth of 7.94% year-over-year. (See all 7 Zen Component Grades here)

_________________________________

⚡ Seeking Alpha's Black Friday Flash Sale: Save Up To 28% through December 9th 

✓ Seeking Alpha Premium — $299 $239/year (save $60) + 7-day free trial for new users

✓ Alpha Picks — $499 $399/year (save $100) | Portfolio up +244% since 2022

✓ Bundle — $798 $574/year (save $224) | Best Value

Rare discounts — won’t see pricing this low again until 2026.

_________________________________

2. Sandisk (NASDAQ: SNDK)

SanDisk Corp. remains a powerhouse in NAND flash storage, supplying the SSDs and embedded solutions driving today’s data boom. Even after a 20% pullback, its momentum is intact—backed by strong analyst support and the fact that it’s currently the #1 ranked stock in the Computer Hardware industry. This is the kind of setup that makes investors take notice.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $226.30 — get current quote

Max 1-year forecast: $300.00

Why we're watching:

• Analyst support: Among the analysts we track, SNDK has 8 Strong Buy ratings and 2 Buy ratings, and only 2 Hold ratings. See the ratings
• For a peek at said ratings, Bank of America researcher Wamsi Mohan (a top 2% rated analyst) recently maintained his Strong Buy rating with a bullish $300 price target, representing +49.80% upside potential.  
• Industry ranking context: SNDK is currently the #1 highest-rated stock in the Computer Hardware industry, which has an Industry Rating of C, making it the standout leader in its sector. (See the whole list here.)
• Zen Rating highlights: A-rated (Strong Buy) stocks average +32.52%/yr, and SNDK's position at the top of its industry suggests it could outperform even this benchmark.
• Component Grades: The company demonstrates exceptional strength with an A grade in Sentiment and B grades in both Growth and Momentum. (See all 7 Zen Component Grades here)

3. Jazz Pharmaceuticals PLC (NASDAQ: JAZZ)

Jazz Pharmaceuticals is gaining serious momentum. The biopharma just hit a 52-week high after releasing promising gastric cancer study results for a new drug, fueling fresh excitement around its growing oncology pipeline. Add in the strong commercial rollout of another much-hyped treatment, and it’s clear why investors are paying close attention to what Jazz is building right now.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $176.93 — get current quote

Max 1-year forecast: $247.00

Why we're watching:

• Analyst support: JAZZ enjoys unanimous Buy-side support among the analysts we track, with 6 Strong Buy ratings and 3 Buy ratings that reflect exceptional conviction across the board. See the ratings
• The stock just got a slew of Buy or Strong Buy ratings after the company announced encouraging trial results. For instance, Needham researcher Ami Fadia (a top 1% rated analyst) reiterated his Buy rating at $202, reinforcing the company's commercial potential for Modeyso in treating ultra-rare H3 K27M mutation glioma with minimal competition.
• Industry ranking context: JAZZ is currently the 6th highest-rated stock in the Biotech industry. But take care: Biotechs have an Industry Rating of F. Jazz does appear to be a standout performer in an otherwise challenging sector.
• Zen Rating highlights: With its A (Strong Buy) Zen Rating, JAZZ is in a class of high-performing stocks that have whipped major indexes with 32.52% average annual returns.
• Component Grades: JAZZ has solid fundamentals (especially for a biotech!) with B grades across Value, Growth, Safety, and Financials — a trifecta for investors who desire gains but want to minimize risk. (See all 7 Zen Component Grades here)

What to Do Next?

• 77 Best Stocks NOW! >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.